Drug intelligence / Profile preview

ENx203

Development stage: Preclinical
Lead developer: Engrail Precision Neuroscience
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ENx203 is a preclinical antibody developed by Enleofen Bio, a spin-out from the National Heart Centre Singapore and Duke-NUS Medical School. It is part of an interleukin-11 (IL-11) antibody platform designed to develop first-in-class therapies for a broad range of fibro-inflammatory diseases, including non-alcoholic steatohepatitis (NASH) and interstitial lung diseases (ILDs). Boehringer Ingelheim acquired worldwide exclusive rights to this platform, including ENx203, and will be solely responsible for its clinical, regulatory, and commercial development.

Targets

IL11 (Interleukin-11)

Beyond the preview

Go deeper on ENx203.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENx203.

Explore the full profile